Locally advanced basal cell carcinoma (laBCC) represents an uncommon, difficult to treat form of skin cancer (1,2). The approval of hedgehog inhibitor (HHI) vismodegib in 2012 opened a novel therapeutic option (2-10). "Drug holidays" have been proposed to increase patients' compliance and adherence which is poor due to the high frequency of adverse effects (AE's) of HHI (3-5), however, up to date, the effect of dose reduction during HHI treatment has not been reported. Herein we report the data of a single center's experience in dose adjustment in 13 patients with laBCC treated with vismodegib.
Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single center experience.
Di Meo N;Zalaudek I.
2019-01-01
Abstract
Locally advanced basal cell carcinoma (laBCC) represents an uncommon, difficult to treat form of skin cancer (1,2). The approval of hedgehog inhibitor (HHI) vismodegib in 2012 opened a novel therapeutic option (2-10). "Drug holidays" have been proposed to increase patients' compliance and adherence which is poor due to the high frequency of adverse effects (AE's) of HHI (3-5), however, up to date, the effect of dose reduction during HHI treatment has not been reported. Herein we report the data of a single center's experience in dose adjustment in 13 patients with laBCC treated with vismodegib.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Woltsche_et_al-2019-Journal_of_the_European_Academy_of_Dermatology_and_Venereology.pdf
Accesso chiuso
Tipologia:
Documento in Versione Editoriale
Licenza:
Copyright Editore
Dimensione
71.07 kB
Formato
Adobe PDF
|
71.07 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.